ScreenerHero

NKTRNektar Therapeutics

NAS · US · Healthcare · Biotechnology · nektar.com
74.02USD-0.68%Mkt Cap: 2.53B $P/E: —

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.53B $
Enterprise Value2.00B $
Revenue (TTM)54.59M $
Gross Profit55.23M $
Net Income (TTM)-164.08M $
Revenue/Share2.247 USD
Last Price74.02 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6402681083
Valuation
P/E (Trailing)—
P/E (Forward)-6.87
PEG0.31
EV/EBITDA-15.36
EV/Revenue36.57
P/S46.62
P/B2.82
EPS (TTM)-6.00
EPS (Forward)-10.84
52W Range
25.3458% of range109.00
52W High109.00 USD
52W Low25.34 USD
Profitability
Gross Margin100.00%
Oper. Margin-412.23%
EBITDA Margin-238.05%
Profit Margin-297.07%
ROE-182.65%
ROA-58.51%
Growth
Revenue Growth-9.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-208.51M $
CapEx (TTM)171.00K $
FCF Margin-246.87%
FCF Yield-5.33%
Net Debt-548.41M $
Net Debt/EBITDA4.22
Balance Sheet
Debt/Equity0.95
Current Ratio10.42
Quick Ratio9.71
Book Value/Sh26.46 USD
Cash/Share20.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateJun 9, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)153.22 USD
Upside (mean)+107.0%
Target Range80.00 USD – 192.00 USD
$80.00+107.0% to mean$192.00
# Analysts9
Ownership
Shares Out.34.14M
Float28.53M
Insiders0.44%
Institutions106.16%
Short Interest
Short Ratio7.0d
Short % Float20.58%
Short % Out.18.65%
Shares Short6.30M
Short (prev mo.)6.90M
Technical
SMA 5069.02 (+7.2%)
SMA 20063.99 (+15.7%)
Beta1.16
S&P 52W Chg18.16%
Avg Vol (30d)654.26K
Avg Vol (10d)612.97K
Technical Indicators
RSI (14)54.5
MACD1.5336
MACD Signal1.6789
MACD Hist.-0.1454
BB Upper77.43 USD
BB Middle73.23 USD
BB Lower69.04 USD
BB Width11.46%
ATR (14)3.146 USD
Vol Ratio (20d)0.93x